News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ligand Pharmaceuticals Inc. (LGND) Announces Positive Preclinical Data for Glucagon Program in Model of Type 1 Diabetes


6/24/2013 9:31:45 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the presentation of a poster titled “Glucagon Receptor Antagonist LGD-6972 Is Efficacious in Streptozotocin-Induced Diabetic Mice” at the 73rd Scientific Sessions of the American Diabetes Association in Chicago. The poster provides data from preclinical studies of Ligand’s novel compound, LGD-6972, demonstrating significant glucose lowering activity in an animal model of type 1 diabetes.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES